Shearman & Sterling advised the underwriters of Entellus Medical, Inc.’s follow-on public offering of 4,059,500 shares of common stock (including 529,500 shares purchased by the underwriters pursuant to their fully exercised option to purchase additional shares). The offer consisted of 2,883,030 shares sold by Entellus and 1,176,470 shares sold by certain of its stockholders.
BofA Merrill Lynch and Piper Jaffray acted as joint book-running managers for the offering, and William Blair acted as co-manager.
Entellus Medical, Inc. (NASDAQ: ENTL) is a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Entellus’ core product lines, XprESS™ Multi-Sinus Dilation Systems, MiniFESS™ Surgical Instruments, XeroGel Nasal Dressing and FocESS™ Imaging & Navigation, combine to enable ENT physicians to conveniently and comfortably perform a broad range of procedures in the office and simplify treatment based in the operating room. Entellus Medical is committed to broadening its product portfolio with high-quality and purposeful innovations for the global ENT market.
The Shearman & Sterling team was led by partner Ilir Mujalovic (New York-Capital Markets); and associates Robert Giannattasio (New York-Capital Markets) and Brian Hurd (New York-Corporate).
Other key members of the team included counsel Jennifer Morton (New York-Financial Institutions Advisory & Financial Regulatory); and associates Maria M. Larsen (New York-Capital Markets), Jon Shields (New York-Capital Markets), Jenny Ding (Financial Institutions Advisory & Financial Regulatory-New York), Benjamin Petersen (Menlo Park-Intellectual Property Transactions), Adam Sternberg (New York-Tax) and Erika Khalek (New York-Corporate).